Information Provided By:
Fly News Breaks for October 4, 2017
BIOC
Oct 4, 2017 | 11:28 EDT
WestPark Capital analyst Lauren Chung said Biocept's new promotion and marketing agreement with Miraca Life Sciences to market Biocept's tests and services in the U.S. will let Biocept to more aggressively boost sales without incurring material cost to the company, and could expand Biocept's reach for tests country wide. Chung rates Biocept a Buy with a $3 price target.
News For BIOC From the Last 2 Days
There are no results for your query BIOC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.